In Reply Dr Fleischhacker suggests that high dropout rates limit the generalizability of our findings. This effectiveness study included participants that clinicians selected as candidates for long-acting injectable antipsychotic medications (ie, they were expected to benefit from depot treatment because they were at risk of poor outcomes due to a history of poor adherence or substance abuse). Thus the findings should be generalizable to typical patients for whom treatment with long-acting injectable antipsychotics is considered.
T. Scott Stroup, Joseph P. McEvoy, Robert M. Hamer. Antipsychotic Medications for Schizophrenia—Reply. JAMA. 2014;312(14):1469. doi:10.1001/jama.2014.10112